News Lundbeck epilepsy injection approved in US New carbamazepine formulation when oral dosing not feasible.
News GW could be next big pharma takeover target UK firm has hired bankers to deal with approaches - press reports.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.